Drug profile

The FDA adverse-event record for Dappl4

12 FDA reports name Dappl4, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2336 of 2,679
by report volume (all drugs)
12
adverse-event reports
8.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Dappl4 ranks #2299 of 2679 by total reports (12). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2299
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Dappl4 has 12 reports now versus 11 in that prior snapshot: 1 more (9.1%).

Report change
+1
Death-coded reports
+0
Death-coded share
−0.8 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Dappl4 changes

Signature read: 12 reports place Dappl4 in the lower third of FDA AER volume (#2336 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
1
Deaths Reported
8.3%
Death-coded share of reports

Active Ingredients

Dappl4

Administration Routes

SubcutaneousUnknown

Species Affected

Dog 12

Most Affected Breeds

Retriever - Golden 1
Rottweiler 1
Akita 1
Terrier - Bull - American Pit 1
Mastiff 1
Hound (unspecified) 1
Weimaraner 1
Chihuahua 1
Crossbred Canine/dog 1
Schnauzer (unspecified) 1

Most Reported Reactions

Vomiting 4
Facial swelling (see also Skin) 4
Emesis 4
Hives (see also Skin) 3
Diarrhoea 3
Bloody diarrhoea 2
Facial swelling (see also 'Skin') 1
Allergic reaction 1
Lethargy (see also Central nervous system depression in 'Neurological') 1
Lateral recumbency 1
Seizure NOS 1
Fixed pupil 1

Outcome Breakdown

Recovered/Normal
6 (50.0%)
Ongoing
4 (33.3%)
Died
1 (8.3%)
Outcome Unknown
1 (8.3%)

Dappl4: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Dappl4 (#2336 of 2,679 by report volume); death-coded 8.3%. PlainBreed drug row · report volume stamp 12 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →